Skin changes on a sermorelin, BPC-157, and TB-500 stack: how to tell what's causing it

Nine months in, the compound your skin reacted to might not be the one you'd guess. A sermorelin, BPC-157, and TB-500 stack touches skin through three separate mechanisms, and they point in different directions. Sorting out which one moved needs more than a mirror check.

Three mechanisms, three different skin stories

Sermorelin is a GHRH analogue. It doesn't touch skin directly, it pushes the pituitary to release more GH, which raises IGF-1. Skin quality shows up on the list of things elevated GH/IGF-1 is associated with, alongside better sleep and joint comfort, at a moderate evidence tier for the GH/IGF-1 elevation itself. That's a slow, general effect: texture and tone drifting over months, not a localized change.

TB-500 works differently. The active fragment most "TB-500" products actually contain (a distinction the label rarely gets right, see below) is linked to cell migration, angiogenesis, and dermal wound healing specifically. That's a mechanistic, weak-tier claim from animal and in-vitro work, but it's the one compound in this stack with a documented pathway straight to skin tissue repair.

BPC-157 is the wild card. Its core mechanism is raising VEGF, a signal that tells the body to grow new blood vessels (angiogenesis), the same pathway behind the community's cancer-discourse anxiety. The concrete, skin-visible version of that concern: physician anecdotes and Reddit reports describing spiderweb angiomas worsening on BPC-157. That's a weak-tier signal, one lab's mechanistic data plus scattered self-report, but it's the only mechanism here that predicts something showing up as a new mark rather than a general improvement.

Three plausible stories, same nine months: GH-driven quality improvement, TB-500-driven repair signaling, or BPC-157-driven vascular change. They're not mutually exclusive, and there's no published trial on any two of these three run together, let alone all three.

The stack has a name, and it's missing a compound

BPC-157 plus TB-500 is the community's "Wolverine stack." Add GHK-Cu, the copper peptide with actual human topical data for collagen and texture, and it becomes the "Glow stack," the one built for skin. A sermorelin, BPC-157, TB-500 combination isn't that. Any skin change you're seeing is a side effect of a stack aimed at soft-tissue repair and GH signaling, not the output of a compound chosen for skin. Worth knowing before you credit the stack with something it wasn't built to do.

What to actually check before you attribute anything

Confirm the vial first. A user who watched his skin darken on what he thought was retatrutide was actually injecting Melanotan II, a compound that broadly raises melanocyte-stimulating hormone. Gray-market sourcing means the label and the contents aren't guaranteed to match. If a skin change is new and sizable, verifying what's actually in the vial comes before mechanism-guessing.

Photograph, don't estimate. The community doesn't have a standard for tracking peptide-specific effects week over week, that's an open gap, not a solved problem. Dated photos of the same site under the same light beat memory for telling a slow GH-driven change from a sudden vascular one.

Watch angiomas specifically. Existing angiomas or unresolved hematomas are the one documented caution point for BPC-157's mechanism, given the VEGF pathway. A new or spreading mark is the kind of change worth bringing to a clinician, not something to wait out.

Isolate one variable at a time if you can. Three compounds started or continued together give you no clean way to attribute a change to any one of them. If the pattern is unclear, dropping one compound while holding the others steady, with a clinician's input, is the only way to get a real signal instead of a guess.

Where this sits going forward

BPC-157 and TB-500 are both on the FDA's Pharmacy Compounding Advisory Committee agenda this week. A yes vote adds them to Category 2 and ends compounding access. Whatever your skin is doing right now, the sourcing and legal picture for two of these three compounds is about to shift, and that's worth knowing before you plan the next few months of the protocol.

None of this replaces a clinician looking at the actual change. It's a map of what could plausibly be moving, so the conversation with your MD starts with a hypothesis instead of a shrug.

Related: how to confirm a BPC-157 side effect, three peptides in one week and no attribution, how to vet what you're actually injecting.

FAQ

Is a new or worsening angioma on BPC-157 a reason to stop?

It's a documented caution point, not a settled verdict. BPC-157's angiogenesis mechanism is the same one flagged for existing hematomas and angiomas, and community reports describe spiderweb angiomas worsening on the compound. A new or spreading mark is worth bringing to a clinician promptly rather than monitoring alone.

Does sermorelin actually improve skin, or is that a GH-axis myth?

Skin quality is on the list of effects associated with elevated GH and IGF-1, at a moderate evidence tier for the hormone elevation itself, though the skin-specific outcome data is thinner than the GH/IGF-1 data. It's a real, documented association, not an established, guaranteed result.

How do I tell which peptide in a multi-compound stack caused a skin change?

There's no shortcut. Dated photos of the same site, a clean baseline before you started, and changing one variable at a time (with a clinician involved) are the only ways to get a real signal. Three compounds started together give you no way to isolate which one moved.

Is BPC-157 still legal to compound after this week's FDA vote?

The FDA's Pharmacy Compounding Advisory Committee is voting this week on adding BPC-157, TB-500, and five other compounds to Category 2, which would end compounding access if approved. Check current status with your source or clinician rather than assuming last month's rules still apply.